NASDAQ:ANAB - AnaptysBio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$73.89 -1.02 (-1.36 %)
(As of 06/25/2018 01:19 PM ET)
Previous Close$73.46
Today's Range$72.80 - $74.98
52-Week Range$20.12 - $134.00
Volume6,693 shs
Average Volume375,251 shs
Market Capitalization$1.76 billion
P/E Ratio-49.13
Dividend YieldN/A
AnaptysBio logoAnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.02
Current Ratio17.57
Quick Ratio17.57


Trailing P/E Ratio-49.13
Forward P/E Ratio-24.31
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales173.64
Cash FlowN/A
Price / CashN/A
Book Value$13.09 per share
Price / Book5.64


EPS (Most Recent Fiscal Year)($1.52)
Net Income$-30,070,000.00
Net MarginsN/A
Return on Equity-16.60%
Return on Assets-15.05%


Outstanding Shares23,500,000

The Truth About Cryptocurrencies

AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How were AnaptysBio's earnings last quarter?

AnaptysBio Inc (NASDAQ:ANAB) posted its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.19. During the same period last year, the firm posted ($0.75) earnings per share. View AnaptysBio's Earnings History.

What price target have analysts set for ANAB?

8 brokerages have issued 1-year target prices for AnaptysBio's shares. Their forecasts range from $40.00 to $180.00. On average, they expect AnaptysBio's share price to reach $138.6250 in the next year. View Analyst Ratings for AnaptysBio.

Who are some of AnaptysBio's key competitors?

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the folowing people:
  • Mr. Hamza Suria, Pres, CEO & Director (Age 42)
  • Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 43)
  • Prof. Marco Londei, Chief Medical Officer (Age 61)
  • Mr. Bob Daniel, Controller
  • Dr. Gerrit Los Ph.D., VP of Pharmacology

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Has AnaptysBio been receiving favorable news coverage?

Media headlines about ANAB stock have been trending positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AnaptysBio earned a coverage optimism score of 0.36 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.50 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by many different of retail and institutional investors. Top institutional investors include FRAZIER HEALTHCARE V, LP (9.93%), BlackRock Inc. (5.96%), OppenheimerFunds Inc. (4.46%), Redmile Group LLC (2.23%), BVF Inc. IL (1.62%) and Millennium Management LLC (1.32%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier, Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio.

Which major investors are selling AnaptysBio stock?

ANAB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Franklin Resources Inc., VHCP Management II LLC, Citigroup Inc., BNP Paribas Arbitrage SA, JPMorgan Chase & Co., Spark Investment Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have sold AnaptysBio company stock in the last year include Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Insider Buying and Selling for AnaptysBio.

Which major investors are buying AnaptysBio stock?

ANAB stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Millennium Management LLC, Artal Group S.A., Royal Bank of Canada, UBS Group AG, BlackRock Inc., Senzar Asset Management LLC and Guggenheim Capital LLC. Company insiders that have bought AnaptysBio stock in the last two years include Healthcare Vii LP Frazier and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio.

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $73.70.

How big of a company is AnaptysBio?

AnaptysBio has a market capitalization of $1.76 billion and generates $10 million in revenue each year. The biotechnology company earns $-30,070,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. AnaptysBio employs 60 workers across the globe.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]

MarketBeat Community Rating for AnaptysBio (ANAB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.